Brief: Sino Biopharmaceutical Says Tqc3721 Inhalation Suspension Approved By Center For Drug Evaluation
09/06/2025 13:13
June 9 (Reuters) - Sino Biopharmaceutical 1177.HK: TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR" APPROVED BY CENTER FOR DRUG EVALUATION BY NMPA CHINA Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up